Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) Trading 0.7% Higher – What’s Next?

Shares of Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) shot up 0.7% on Monday . The stock traded as high as $5.84 and last traded at $5.76. 37,477 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 569,795 shares. The stock had previously closed at $5.72.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright raised their target price on shares of Neuphoria Therapeutics Inc. – Common Stock from $8.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, February 4th.

Neuphoria Therapeutics Inc. – Common Stock Stock Up 1.8 %

The firm has a 50 day simple moving average of $5.04.

Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) last released its earnings results on Friday, February 14th. The company reported ($1.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.01) by $0.78. The firm had revenue of $660 billion for the quarter. On average, sell-side analysts anticipate that Neuphoria Therapeutics Inc. – Common Stock will post -1.56 earnings per share for the current year.

Institutional Trading of Neuphoria Therapeutics Inc. – Common Stock

An institutional investor recently bought a new position in Neuphoria Therapeutics Inc. – Common Stock stock. Jane Street Group LLC purchased a new position in Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 13,311 shares of the company’s stock, valued at approximately $46,000. Jane Street Group LLC owned about 0.82% of Neuphoria Therapeutics Inc. – Common Stock as of its most recent filing with the Securities & Exchange Commission. 15.90% of the stock is currently owned by institutional investors and hedge funds.

About Neuphoria Therapeutics Inc. – Common Stock

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.